FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255351744> ?p ?o ?g. }

• W2255351744 abstract "ABSTRACT Aim: Many patients (pts) with biliary cancer present advanced and unresectable disease. TACE has been effective in prolonging survival of pts with hepatocellular carcinoma; the aim of this analysis is to assess its safety and efficacy in biliary cancer. Methods: We retrospectively collected data on pts with histologically-proven unresectable biliary cancer consecutively treated with TACE at our Institution. TACE was performed with infusion of 2 ml of microspheres preloaded with doxorubicin (50 mg) into the tumor-supplying vessels. The treatment was repeated at a minimum of 4-weeks interval. Follow-up investigations after 4 weeks included contrast-enhanced multislice spiral CT and laboratory control. Results: From January 2011 to December 2013 52 TACE (range 1-7 per pts) were performed in 23 pts with the following characteristics: M/F 10/13; median age 64 (range 32-78); intrahepatic cholangiocarcinoma: 18, extrahepatic cholangiocarcinoma: 3 and gallbladder cancer: 2; unifocal/multifocal disease 10/13; 14 pts presented a minimal extrahepatic disease. According to RECIST criteria, best hepatic response to treatment was complete response in 1 pts, partial response in 5 pts and stable disease in 17 pts. 2 pts became resectable and underwent liver resection after TACE. No hepatic progression was observed within 4 weeks after procedure, while 4 pts progressed in extrahepatic sites (17%). The treatment was well tolerated with no deaths and no acute liver failure. Only 1 pts had an hepatic abscess as major complication; all other pts experienced mild side effects as fever, nausea, general malaise, loss of appetite and abdominal pain (PES, Post Embolization Syndrome). This syndrome occurred in the first 72 hours after procedure and resolved with conservative therapy alone. At the time of analysis 12 pts are alive and 4 of them have not progressed yet. Data are still immature for survival analysis. Conclusions: TACE is an effective and safe procedure with a high local disease control rate in unresectable biliary tract cancer and might be able to improve the outcome in this setting. Further studies are needed to confirm these preliminary data and to set the better timing for TACE integration with systemic chemotherapy. Disclosure: All authors have declared no conflicts of interest." @default.
• W2255351744 created "2016-06-24" @default.
• W2255351744 creator A5011192035 @default.
• W2255351744 creator A5014696489 @default.
• W2255351744 creator A5016288779 @default.
• W2255351744 creator A5016984915 @default.
• W2255351744 creator A5021631368 @default.
• W2255351744 creator A5021781945 @default.
• W2255351744 creator A5028325185 @default.
• W2255351744 creator A5034356923 @default.
• W2255351744 creator A5037546463 @default.
• W2255351744 creator A5041272635 @default.
• W2255351744 creator A5045717698 @default.
• W2255351744 creator A5051613962 @default.
• W2255351744 creator A5062254561 @default.
• W2255351744 creator A5084382735 @default.
• W2255351744 date "2014-09-01" @default.
• W2255351744 modified "2023-09-27" @default.
• W2255351744 title "Safety and Efficacy of Transcatheter Arterial Chemoembolization (Tace) in Unresectable Biliary Cancer" @default.
• W2255351744 doi "https://doi.org/10.1093/annonc/mdu334.112" @default.
• W2255351744 hasPublicationYear "2014" @default.
• W2255351744 type Work @default.
• W2255351744 sameAs 2255351744 @default.
• W2255351744 citedByCount "0" @default.
• W2255351744 crossrefType "journal-article" @default.
• W2255351744 hasAuthorship W2255351744A5011192035 @default.
• W2255351744 hasAuthorship W2255351744A5014696489 @default.
• W2255351744 hasAuthorship W2255351744A5016288779 @default.
• W2255351744 hasAuthorship W2255351744A5016984915 @default.
• W2255351744 hasAuthorship W2255351744A5021631368 @default.
• W2255351744 hasAuthorship W2255351744A5021781945 @default.
• W2255351744 hasAuthorship W2255351744A5028325185 @default.
• W2255351744 hasAuthorship W2255351744A5034356923 @default.
• W2255351744 hasAuthorship W2255351744A5037546463 @default.
• W2255351744 hasAuthorship W2255351744A5041272635 @default.
• W2255351744 hasAuthorship W2255351744A5045717698 @default.
• W2255351744 hasAuthorship W2255351744A5051613962 @default.
• W2255351744 hasAuthorship W2255351744A5062254561 @default.
• W2255351744 hasAuthorship W2255351744A5084382735 @default.
• W2255351744 hasBestOaLocation W22553517441 @default.
• W2255351744 hasConcept C121608353 @default.
• W2255351744 hasConcept C126322002 @default.
• W2255351744 hasConcept C141071460 @default.
• W2255351744 hasConcept C2776534502 @default.
• W2255351744 hasConcept C2776694085 @default.
• W2255351744 hasConcept C2778019345 @default.
• W2255351744 hasConcept C2778455285 @default.
• W2255351744 hasConcept C2778822529 @default.
• W2255351744 hasConcept C2779384505 @default.
• W2255351744 hasConcept C2779984678 @default.
• W2255351744 hasConcept C2780580376 @default.
• W2255351744 hasConcept C2909135397 @default.
• W2255351744 hasConcept C71924100 @default.
• W2255351744 hasConcept C90924648 @default.
• W2255351744 hasConceptScore W2255351744C121608353 @default.
• W2255351744 hasConceptScore W2255351744C126322002 @default.
• W2255351744 hasConceptScore W2255351744C141071460 @default.
• W2255351744 hasConceptScore W2255351744C2776534502 @default.
• W2255351744 hasConceptScore W2255351744C2776694085 @default.
• W2255351744 hasConceptScore W2255351744C2778019345 @default.
• W2255351744 hasConceptScore W2255351744C2778455285 @default.
• W2255351744 hasConceptScore W2255351744C2778822529 @default.
• W2255351744 hasConceptScore W2255351744C2779384505 @default.
• W2255351744 hasConceptScore W2255351744C2779984678 @default.
• W2255351744 hasConceptScore W2255351744C2780580376 @default.
• W2255351744 hasConceptScore W2255351744C2909135397 @default.
• W2255351744 hasConceptScore W2255351744C71924100 @default.
• W2255351744 hasConceptScore W2255351744C90924648 @default.
• W2255351744 hasLocation W22553517441 @default.
• W2255351744 hasOpenAccess W2255351744 @default.
• W2255351744 hasPrimaryLocation W22553517441 @default.
• W2255351744 isParatext "false" @default.
• W2255351744 isRetracted "false" @default.
• W2255351744 magId "2255351744" @default.
• W2255351744 workType "article" @default.